1 of 4
Immunoglobulin Market Overview:
The global immunoglobulin was valued at $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs) or antibodies are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and are specific in their action. They are obtained from blood through the process of fractionation and are purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously for the treatment of various deficiencies.
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the immunoglobulin market. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the market growth. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin is anticipated to hamper the market growth.
On the contrary, significant investment in healthcare sector is predicted to create lucrative opportunities in the near future.
The global immunoglobulin market is characterized based on application, product type, mode of delivery, and region. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is classified into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Immunoglobulin Market:
The study provides an in-depth analysis of the immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the trends in the immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Immunoglobulin Key Market Segments:
By Application
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy
Primary Immunodeficiency Disease
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Inflammatory Myopathies
Specific Antibody Deficiency
Guillain-Barre Syndrome
Others
By Product
IgG
IgA
IgM
IgE
IgD
By Mode of Delivery
Intravenous
5% Concentration
10% Concentration
Others
Sucutaneous
16.5% Concentration
20% Concentration
Others
By Region
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
France
Austria
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Saudi Arabia
Brazil
Turkey
Argentina
Rest of LAMEA
Key Players Profiled
Baxter international Inc.
CSL Ltd.
Grifols S.A.
Octapharma AG
Kedrion Biopharma Inc.
LFB group
Biotest AG
China Biologics Products, Inc.
Shire Plc.(Baxalta)
Bayer AG
The other players of the immunoglobulin market include (companies not profiled in the report):
Hualan Biological Engineering Inc.
Omrix Biopharmaceuticals Ltd.
Behring GmbH
Shanghai RAAS Blood Products Co., Ltd.
Option Care Enterprises, Inc.
ADMA Biologics, Inc.
BioScrip, Inc
The global immunoglobulin was valued at $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs) or antibodies are glycoproteins produced in the blood plasma in response to the antigens, which are foreign to the host system. They are highly complex entities and are specific in their action. They are obtained from blood through the process of fractionation and are purified for therapeutic and non-therapeutic applications. In therapeutics, they are administered intravenously for the treatment of various deficiencies.
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia & others and rise in adoption of immunoglobulin treatments for the treatment of various autoimmune disorders majorly drive the growth of the immunoglobulin market. Further, the increase in approval of immunoglobulin drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and government is expected to accelerate the market growth. However, stringent government regulations, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin is anticipated to hamper the market growth.
On the contrary, significant investment in healthcare sector is predicted to create lucrative opportunities in the near future.
The global immunoglobulin market is characterized based on application, product type, mode of delivery, and region. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is classified into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Immunoglobulin Market:
The study provides an in-depth analysis of the immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided.
A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
An extensive analysis of the key segments of the industry helps to understand the trends in the immunoglobulin market globally.
Key players and their strategies are provided to understand the competitive outlook of the industry.
Immunoglobulin Key Market Segments:
By Application
Hypogammaglobulinemia
Chronic Inflammatory Demyelinating Polyneuropathy
Primary Immunodeficiency Disease
Myasthenia Gravis
Multifocal Motor Neuropathy
Idiopathic Thrombocytopenic Purpura (ITP)
Inflammatory Myopathies
Specific Antibody Deficiency
Guillain-Barre Syndrome
Others
By Product
IgG
IgA
IgM
IgE
IgD
By Mode of Delivery
Intravenous
5% Concentration
10% Concentration
Others
Sucutaneous
16.5% Concentration
20% Concentration
Others
By Region
North America
U.S.
Canada
Mexico
Europe
UK
France
Germany
Italy
France
Austria
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Saudi Arabia
Brazil
Turkey
Argentina
Rest of LAMEA
Key Players Profiled
Baxter international Inc.
CSL Ltd.
Grifols S.A.
Octapharma AG
Kedrion Biopharma Inc.
LFB group
Biotest AG
China Biologics Products, Inc.
Shire Plc.(Baxalta)
Bayer AG
The other players of the immunoglobulin market include (companies not profiled in the report):
Hualan Biological Engineering Inc.
Omrix Biopharmaceuticals Ltd.
Behring GmbH
Shanghai RAAS Blood Products Co., Ltd.
Option Care Enterprises, Inc.
ADMA Biologics, Inc.
BioScrip, Inc
Note: Product cover images may vary from those shown
2 of 4
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO perspective
Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Market share analysis, 2017
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of immunodeficiency diseases
3.5.1.2. Increase in adoption of immunoglobulin
3.5.1.3. Increase in incidence of bleeding disorders
3.5.1.4. Surge in geriatric population
3.5.2. Restraints
3.5.2.1. Stringent government regulations
3.5.2.2. High cost of therapy
3.5.3. Opportunities
3.5.3.1. Opportunities in emerging economies
3.5.3.2. Development of cost-effective therapeutics through large-scale production
Chapter 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. HYPOGAMMAGLOBULINEMIA
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Idiopathic thrombocytopenic purpura
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11. Others
4.11.1. Market size and forecast
Chapter 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
5.1. Overview
5.1.1. IGG
5.1.2. Key market trends
5.1.3. Clinical interpretations
5.1.4. IGA
5.1.5. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGM
5.1.8. Key Market Trends
5.1.9. Clinical interpretation
5.1.10. IGE
5.1.11. Key Market Trend
5.1.12. Clinical interpretation
5.1.13. IGD
5.1.14. Key Market Trends
5.1.15. Clinical interpretation
Chapter 6: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY
6.1. Overview
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Key Market Trends
6.2.2. Market size and forecast
6.2.2.1. 5% concentration
6.2.3. Market size and forecast
6.2.3.1. 10% Concentration
6.2.4. Market size and forecast
6.2.4.1. Other Concentrations
6.2.5. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Key Market Trends
6.3.2. Market size and forecast
6.3.2.1. 5% Concentration
6.3.3. Market size and forecast
6.3.3.1. 16.5% Concentration
6.3.4. Market size and forecast
6.3.4.1. 20% Concentration
6.3.5. Market size and forecast
6.3.5.1. Other Concentration
6.3.6. Market size and forecast
Chapter 7: IMMUNOGLOBULIN MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. North America market size & forecast, by country
7.2.3. North America market size & forecast, by application
7.2.4. North America market size & forecast, by mode of delivery
7.2.4.1. U.S. market size & forecast
7.2.4.2. Canada market size & forecast
7.2.4.3. Mexico market size & forecast
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Europe market size & forecast for immunoglobulin market, by country
7.3.3. Europe market size & forecast, by application
7.3.4. Europe market size & forecast, by mode of delivery
7.3.4.1. Germany market size & forecast
7.3.4.2. France market size & forecast
7.3.4.3. UK market size & forecast
7.3.4.4. Italy market size & forecast
7.3.4.5. Spain market size & forecast
7.3.4.6. Russia market size & forecast
7.3.4.7. Rest of Europe market size & forecast
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size & forecast, by country
7.4.3. Asia-Pacific market size & forecast, by application
7.4.4. Asia-Pacific market size & forecast, by mode of delivery
7.4.4.1. Japan market size & forecast
7.4.4.2. China market size & forecast
7.4.4.3. India market size & forecast
7.4.4.4. Australia market size & forecast
7.4.4.5. South Korea market size & forecast
7.4.4.6. Taiwan market size & forecast
7.4.4.7. Rest of Asia-Pacific market size & forecast
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. LAMEA market size & forecast, by country
7.5.3. LAMEA market size & forecast, by application
7.5.4. LAMEA market size & forecast, by mode of delivery
7.5.4.1. Brazil market size & forecast
7.5.4.2. South Africa market size & forecast
7.5.4.3. Saudi Arabia market size & forecast
7.5.4.4. Argentina market size & forecast
7.5.4.5. Rest of LAMEA market size & forecast
Chapter 8: COMPANY PROFILES
8.1. Baxter International Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. BIoTest AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. CSL Limited
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Grifols S.A.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. LFB SA (LFB BIoTechnologies SAS)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Octapharma AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Bayer AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. Kedrion Biopharma Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Shire Plc.(Baxalta)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. China Biologic Products, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
List Of Tables
Table 01. Global Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 02. Global Immunoglobulin Market, By Application, 2017-2025 (Kilogram)
Table 03. Global Immunoglobulin Market, For Hypogammaglobulinemia, By Region, 2017-2025 ($Million)
Table 04. Global Immunoglobulin Market, For Cipd, By Region, 2017-2025 ($Million)
Table 05. Global Immunoglobulin Market, For Cipd, By Region, 2017-2025 (Kilograms)
Table 06. Global Immunoglobulin Market, For Idiopathic Thrombocytopenic Purpura By Region, 2017-2025 ($Million)
Table 07. Global Immunoglobulin Market, For Idiopathic Thrombocytopenic Purpura By Region, 2017-2025 (Kilograms)
Table 08. Global Immunoglobulin Market, For Myasthenia Gravis (Mg), By Region, 2017-2025 ($Million)
Table 09. Global Immunoglobulin Market, For Myasthenia Gravis (Mg), By Region, 2017-2025 (Kilograms)
Table 10. Global Immunoglobulin Market, For Multifocal Motor Neuropathy, By Region, 2017-2025 ($Million)
Table 11. Global Immunoglobulin Market, For Multifocal Motor Neuropathy, By Region, 2017-2025 (Kilograms)
Table 12. Global Immunoglobulin Market, For Idiopathic Thrombocytopenic Purpura (Itp), By Region, 2017-2025 ($Million)
Table 13. Global Immunoglobulin Market, For Idiopathic Thrombocytopenic Purpura (Itp), By Region, 2017-2025 (Kilograms)
Table 14. Global Immunoglobulin Market, For Inflammatory Myopathy, By Region, 2017-2025 ($Million)
Table 15. Global Immunoglobulin Market, For Inflammatory Myopathy, By Region, 2017-2025 (Kilograms)
Table 16. Global Immunoglobulin Market, For Specific Antibody Deficiency (Sad), By Region, 2017-2025 ($Million)
Table 17. Global Immunoglobulin Market, For Specific Antibody Deficiency (Sad), By Region, 2017-2025 (Kilograms)
Table 18. Global Immunoglobulin Market, For Guillain-Barre Syndrome, By Region, 2017-2025 ($Million)
Table 19. Global Immunoglobulin Market, For Guillain-Barre Syndrome), By Region, 2017-2025 (Kilograms)
Table 20. Global Immunoglobulin Market, For Others, By Region, 2017-2025 ($Million)
Table 21. Global Immunoglobulin Market, For Others, By Region, 2017-2025 (Kilograms)
Table 22. Global Immunoglobulin Market, By Mode Of Delivery, 2017-2025 ($Million)
Table 23. Global Immunoglobulin Market, By Mode Of Delivery, 2017-2025 (Kilograms)
Table 24. Immunoglobulin Market, For Intravenous, By Region, 2017-2025 ($Million)
Table 25. Immunoglobulin Market, For Intravenous, By Region, 2017-2025 (Kilograms)
Table 26. Immunoglobulin Market, For 5% Concentration, By Region, 2017-2025 ($Million)
Table 27. Immunoglobulin Market, For 10% Concentration, 2017-2025 ($Million)
Table 28. Global Immunoglobulin Market, For Other Concentrations, 2017-2025 ($Million)
Table 29. Immunoglobulin Market, For Subcutaneous Mode Of Delivery, By Region, 2017-2025 ($Million)
Table 30. Immunoglobulin Market, For Subcutaneous Mode Of Delivery, By Region, 2017-2025 (Kilograms)
Table 31. Global Immunoglobulin Market, By Region, 2017-2025 ($Million)
Table 32. Global Immunoglobulin Market, By Region, 2017-2025 (Kilograms)
Table 33. North America Immunoglobulin Market, By Country, 2017-2025 ($Million)
Table 34. North America Immunoglobulin Market, By Country, 2017-2025 (Kilograms)
Table 35. North America Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 36. North America Immunoglobulin Market, By Target Area, 2017-2025 ($Million)
Table 37. Europe Immunoglobulin Market, By Country, 2017-2025 ($Million)
Table 38. Europe Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 39. Europe Immunoglobulin Market, By Mode Of Delivery, 2017-2025 ($Million)
Table 40. Asia-Pacific Immunoglobulin Market, By Country, 2017-2025 ($Million)
Table 41. Asia-Pacific Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 42. Asia-Pacific Immunoglobulin Market, By Mode Of Delivery, 2017-2025 ($Million)
Table 43. LAMEA Immunoglobulin Market, By Country, 2017-2025 ($Million)
Table 44. LAMEA Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 45. LAMEA Immunoglobulin Market, By Mode Of Delivery, 2017-2025 ($Million)
Table 46. Baxter: Company Snapshot
Table 47. Baxter: Operating Segments
Table 48. Baxter: Product Portfolio
Table 49. BIoTest: Company Snapshot
Table 50. BIoTest: Operating Segments
Table 51. BIoTest: Operating Segment
Table 52. Csl: Company Snapshot
Table 53. Csl: Product Segments
Table 54. Csl: Product Portfolio
Table 55. Grifols: Company Snapshot
Table 56. Grifols: Operating Segments
Table 57. Grifols: Product Portfolio
Table 58. Lfb: Company Snapshot
Table 59. Lfb: Product Segments
Table 60. Lfb: Product Portfolio
Table 61. Octapharma: Company Snapshot
Table 62. Octapharma: Product Segments
Table 63. Octapharma: Product Portfolio
Table 64. Bayer: Company Snapshot
Table 65. Bayer: Operating Segments
Table 66. Kedrion: Company Snapshot
Table 67. Kedrion: Product Portfolio
Table 68. Shire: Company Snapshot
Table 69. Shire: Product Portfolio
Table 70. China Biologic Company Snapshot
Table 71. China Biologic Product Portfolio
List of Figures
Figure 01. Immunoglobulin Market Segmentation
Figure 02. Top Winning Strategies, By Year, 2015-2018*
Figure 03. Top Winning Strategies, By Development, 2015-2018* (%)
Figure 04. Top Winning Strategies, By Company, 2015-2018*
Figure 05. Low Bargaining Power Of Suppliers
Figure 06. High Bargaining Power Of Buyers
Figure 07. High Threat Of Substitution
Figure 08. High Threat Of New Entrants
Figure 09. High Competitive Rivalry
Figure 10. Market Share Analysis, 2017
Figure 11. Global Immunoglobulin Market: Drivers, Restraints, And Opportunities
Figure 01. U.S. Immunoglobulin Market, 2017-2025 ($ Million)
Figure 02. Canada Immunoglobulin Market, 2017-2025 ($ Million)
Figure 03. Mexico Immunoglobulin Market, 2017-2025 ($ Million)
Figure 04. Germany Immunoglobulin Market, 2017-2025 ($ Million)
Figure 05. France Immunoglobulin Market, 2017-2025 ($ Million)
Figure 06. UK Immunoglobulin Market, 2017-2025 ($ Million)
Figure 07. Italy Immunoglobulin Market, 2017-2025 ($ Million)
Figure 08. Spain Immunoglobulin Market, 2017-2025 ($ Million)
Figure 09. Russia Immunoglobulin Market, 2017-2025 ($ Million)
Figure 10. Rest Of Europe Immunoglobulin Market, 2017-2025 ($ Million)
Figure 11. Japan Immunoglobulin Market, 2017-2025 ($ Million)
Figure 12. China Immunoglobulin Market, 2017-2025 ($ Million)
Figure 13. India Immunoglobulin Market, 2017-2025 ($ Million)
Figure 14. Australia Immunoglobulin Market, 2017-2025 ($ Million)
Figure 15. Australia Immunoglobulin Market, 2017-2025 ($ Million)
Figure 16. Taiwan Immunoglobulin Market, 2017-2025 ($ Million)
Figure 17. Rest Of Asia-Pacific Immunoglobulin Market, 2017-2025 ($ Million)
Figure 18. Brazil Immunoglobulin Market, 2017-2025 ($ Million)
Figure 19. South Africa Immunoglobulin Market, 2017-2025 ($ Million)
Figure 20. Saudi Arabia Immunoglobulin Market, 2017-2025 ($Million)
Figure 21. Argentina Immunoglobulin Market, 2017-2025 ($Million)
Figure 22. Rest Of LAMEA Immunoglobulin Market, 2017-2025 ($Million)
Figure 23. Baxter: Net Sales, 2015-2017 ($Million)
Figure 24. Baxter: Revenue Share By Segment, 2017 (%)
Figure 25. Baxter: Revenue Share By Geography, 2017 (%)
Figure 26. BIoTest: Net Sales, 2015-2017 ($Million)
Figure 27. BIoTest: Revenue Share By Segment, 2017 (%)
Figure 28. BIoTest: Revenue Share By Geography, 2017 (%)
Figure 29. Csl: Net Sales, 2015-2017 ($Million)
Figure 30. Csl: Revenue Share By Segment, 2017 (%)
Figure 31. Csl: Revenue Share By Geography, 2017 (%)
Figure 32. Grifols: Net Sales, 2015-2017 ($Million)
Figure 33. Grifols: Revenue Share By Segment, 2017 (%)
Figure 34. Grifols: Revenue Share By Geography, 2017 (%)
Figure 35. Lfb: Net Sales, 20142016 ($Million)
Figure 36. Lfb: Revenue Share By Product Segment, 2016 (%)
Figure 37. Lfb: Revenue Share By Geography, 2016 (%)
Figure 38. Octapharma: Net Sales, 2015-2017 ($Million)
Figure 39. Bayer: Net Sales, 2015-2017 ($Million)
Figure 40. Bayer: Revenue Share By Segment, 2017 (%)
Figure 41. Bayer: Revenue Share By Geography, 2017 (%)
Figure 42. Kedrion: Net Sales, 2015-2017 ($Million)
Figure 43. Kedrion: Revenue Share By Geography, 2017 (%)
Figure 44. Shire: Net Sales, 2015-2017 ($Million)
Figure 45. Shire: Revenue Share By Product, 2017 (%)
Figure 46. Shire: Revenue Share By Geography, 2017 (%)
Figure 47. China Biologic Net Sales, 2015-2017 ($Million)
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO perspective
Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top Winning Strategies
3.3. Porters five forces analysis
3.4. Market share analysis, 2017
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of immunodeficiency diseases
3.5.1.2. Increase in adoption of immunoglobulin
3.5.1.3. Increase in incidence of bleeding disorders
3.5.1.4. Surge in geriatric population
3.5.2. Restraints
3.5.2.1. Stringent government regulations
3.5.2.2. High cost of therapy
3.5.3. Opportunities
3.5.3.1. Opportunities in emerging economies
3.5.3.2. Development of cost-effective therapeutics through large-scale production
Chapter 4: IMMUNOGLOBULIN MARKET, BY APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. HYPOGAMMAGLOBULINEMIA
4.2.1. Market size and forecast
4.3. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
4.3.1. Market size and forecast
4.4. Idiopathic thrombocytopenic purpura
4.4.1. Market size and forecast
4.5. Myasthenia Gravis
4.5.1. Market size and forecast
4.6. MULTIFOCAL MOTOR NEUROPATHY
4.6.1. Market size and forecast
4.7. Idiopathic thrombocytopenic purpura (ITP)
4.7.1. Market size and forecast
4.8. INFLAMMATORY MYOPATHIES
4.8.1. Market size and forecast
4.9. Specific antibody deficiency
4.9.1. Market size and forecast
4.10. Guillain-Barre syndrome
4.10.1. Market size and forecast
4.11. Others
4.11.1. Market size and forecast
Chapter 5: IMMUNOGLOBULIN MARKET, BY PRODUCT
5.1. Overview
5.1.1. IGG
5.1.2. Key market trends
5.1.3. Clinical interpretations
5.1.4. IGA
5.1.5. Key Market Trends
5.1.6. Clinical interpretation
5.1.7. IGM
5.1.8. Key Market Trends
5.1.9. Clinical interpretation
5.1.10. IGE
5.1.11. Key Market Trend
5.1.12. Clinical interpretation
5.1.13. IGD
5.1.14. Key Market Trends
5.1.15. Clinical interpretation
Chapter 6: IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY
6.1. Overview
6.1.1. Market size and forecast
6.2. INTRAVENOUS MODE OF DELIVERY
6.2.1. Key Market Trends
6.2.2. Market size and forecast
6.2.2.1. 5% concentration
6.2.3. Market size and forecast
6.2.3.1. 10% Concentration
6.2.4. Market size and forecast
6.2.4.1. Other Concentrations
6.2.5. Market size and forecast
6.3. SUBCUTANEOUS MODE OF DELIVERY
6.3.1. Key Market Trends
6.3.2. Market size and forecast
6.3.2.1. 5% Concentration
6.3.3. Market size and forecast
6.3.3.1. 16.5% Concentration
6.3.4. Market size and forecast
6.3.4.1. 20% Concentration
6.3.5. Market size and forecast
6.3.5.1. Other Concentration
6.3.6. Market size and forecast
Chapter 7: IMMUNOGLOBULIN MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. North America market size & forecast, by country
7.2.3. North America market size & forecast, by application
7.2.4. North America market size & forecast, by mode of delivery
7.2.4.1. U.S. market size & forecast
7.2.4.2. Canada market size & forecast
7.2.4.3. Mexico market size & forecast
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Europe market size & forecast for immunoglobulin market, by country
7.3.3. Europe market size & forecast, by application
7.3.4. Europe market size & forecast, by mode of delivery
7.3.4.1. Germany market size & forecast
7.3.4.2. France market size & forecast
7.3.4.3. UK market size & forecast
7.3.4.4. Italy market size & forecast
7.3.4.5. Spain market size & forecast
7.3.4.6. Russia market size & forecast
7.3.4.7. Rest of Europe market size & forecast
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Asia-Pacific market size & forecast, by country
7.4.3. Asia-Pacific market size & forecast, by application
7.4.4. Asia-Pacific market size & forecast, by mode of delivery
7.4.4.1. Japan market size & forecast
7.4.4.2. China market size & forecast
7.4.4.3. India market size & forecast
7.4.4.4. Australia market size & forecast
7.4.4.5. South Korea market size & forecast
7.4.4.6. Taiwan market size & forecast
7.4.4.7. Rest of Asia-Pacific market size & forecast
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. LAMEA market size & forecast, by country
7.5.3. LAMEA market size & forecast, by application
7.5.4. LAMEA market size & forecast, by mode of delivery
7.5.4.1. Brazil market size & forecast
7.5.4.2. South Africa market size & forecast
7.5.4.3. Saudi Arabia market size & forecast
7.5.4.4. Argentina market size & forecast
7.5.4.5. Rest of LAMEA market size & forecast
Chapter 8: COMPANY PROFILES
8.1. Baxter International Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. BIoTest AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. CSL Limited
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Grifols S.A.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. LFB SA (LFB BIoTechnologies SAS)
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.6. Octapharma AG
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Bayer AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments
8.8. Kedrion Biopharma Inc.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Shire Plc.(Baxalta)
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. China Biologic Products, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
List Of Tables
Table 01. Global Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 02. Global Immunoglobulin Market, By Application, 2017-2025 (Kilogram)
Table 03. Global Immunoglobulin Market, For Hypogammaglobulinemia, By Region, 2017-2025 ($Million)
Table 04. Global Immunoglobulin Market, For Cipd, By Region, 2017-2025 ($Million)
Table 05. Global Immunoglobulin Market, For Cipd, By Region, 2017-2025 (Kilograms)
Table 06. Global Immunoglobulin Market, For Idiopathic Thrombocytopenic Purpura By Region, 2017-2025 ($Million)
Table 07. Global Immunoglobulin Market, For Idiopathic Thrombocytopenic Purpura By Region, 2017-2025 (Kilograms)
Table 08. Global Immunoglobulin Market, For Myasthenia Gravis (Mg), By Region, 2017-2025 ($Million)
Table 09. Global Immunoglobulin Market, For Myasthenia Gravis (Mg), By Region, 2017-2025 (Kilograms)
Table 10. Global Immunoglobulin Market, For Multifocal Motor Neuropathy, By Region, 2017-2025 ($Million)
Table 11. Global Immunoglobulin Market, For Multifocal Motor Neuropathy, By Region, 2017-2025 (Kilograms)
Table 12. Global Immunoglobulin Market, For Idiopathic Thrombocytopenic Purpura (Itp), By Region, 2017-2025 ($Million)
Table 13. Global Immunoglobulin Market, For Idiopathic Thrombocytopenic Purpura (Itp), By Region, 2017-2025 (Kilograms)
Table 14. Global Immunoglobulin Market, For Inflammatory Myopathy, By Region, 2017-2025 ($Million)
Table 15. Global Immunoglobulin Market, For Inflammatory Myopathy, By Region, 2017-2025 (Kilograms)
Table 16. Global Immunoglobulin Market, For Specific Antibody Deficiency (Sad), By Region, 2017-2025 ($Million)
Table 17. Global Immunoglobulin Market, For Specific Antibody Deficiency (Sad), By Region, 2017-2025 (Kilograms)
Table 18. Global Immunoglobulin Market, For Guillain-Barre Syndrome, By Region, 2017-2025 ($Million)
Table 19. Global Immunoglobulin Market, For Guillain-Barre Syndrome), By Region, 2017-2025 (Kilograms)
Table 20. Global Immunoglobulin Market, For Others, By Region, 2017-2025 ($Million)
Table 21. Global Immunoglobulin Market, For Others, By Region, 2017-2025 (Kilograms)
Table 22. Global Immunoglobulin Market, By Mode Of Delivery, 2017-2025 ($Million)
Table 23. Global Immunoglobulin Market, By Mode Of Delivery, 2017-2025 (Kilograms)
Table 24. Immunoglobulin Market, For Intravenous, By Region, 2017-2025 ($Million)
Table 25. Immunoglobulin Market, For Intravenous, By Region, 2017-2025 (Kilograms)
Table 26. Immunoglobulin Market, For 5% Concentration, By Region, 2017-2025 ($Million)
Table 27. Immunoglobulin Market, For 10% Concentration, 2017-2025 ($Million)
Table 28. Global Immunoglobulin Market, For Other Concentrations, 2017-2025 ($Million)
Table 29. Immunoglobulin Market, For Subcutaneous Mode Of Delivery, By Region, 2017-2025 ($Million)
Table 30. Immunoglobulin Market, For Subcutaneous Mode Of Delivery, By Region, 2017-2025 (Kilograms)
Table 31. Global Immunoglobulin Market, By Region, 2017-2025 ($Million)
Table 32. Global Immunoglobulin Market, By Region, 2017-2025 (Kilograms)
Table 33. North America Immunoglobulin Market, By Country, 2017-2025 ($Million)
Table 34. North America Immunoglobulin Market, By Country, 2017-2025 (Kilograms)
Table 35. North America Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 36. North America Immunoglobulin Market, By Target Area, 2017-2025 ($Million)
Table 37. Europe Immunoglobulin Market, By Country, 2017-2025 ($Million)
Table 38. Europe Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 39. Europe Immunoglobulin Market, By Mode Of Delivery, 2017-2025 ($Million)
Table 40. Asia-Pacific Immunoglobulin Market, By Country, 2017-2025 ($Million)
Table 41. Asia-Pacific Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 42. Asia-Pacific Immunoglobulin Market, By Mode Of Delivery, 2017-2025 ($Million)
Table 43. LAMEA Immunoglobulin Market, By Country, 2017-2025 ($Million)
Table 44. LAMEA Immunoglobulin Market, By Application, 2017-2025 ($Million)
Table 45. LAMEA Immunoglobulin Market, By Mode Of Delivery, 2017-2025 ($Million)
Table 46. Baxter: Company Snapshot
Table 47. Baxter: Operating Segments
Table 48. Baxter: Product Portfolio
Table 49. BIoTest: Company Snapshot
Table 50. BIoTest: Operating Segments
Table 51. BIoTest: Operating Segment
Table 52. Csl: Company Snapshot
Table 53. Csl: Product Segments
Table 54. Csl: Product Portfolio
Table 55. Grifols: Company Snapshot
Table 56. Grifols: Operating Segments
Table 57. Grifols: Product Portfolio
Table 58. Lfb: Company Snapshot
Table 59. Lfb: Product Segments
Table 60. Lfb: Product Portfolio
Table 61. Octapharma: Company Snapshot
Table 62. Octapharma: Product Segments
Table 63. Octapharma: Product Portfolio
Table 64. Bayer: Company Snapshot
Table 65. Bayer: Operating Segments
Table 66. Kedrion: Company Snapshot
Table 67. Kedrion: Product Portfolio
Table 68. Shire: Company Snapshot
Table 69. Shire: Product Portfolio
Table 70. China Biologic Company Snapshot
Table 71. China Biologic Product Portfolio
List of Figures
Figure 01. Immunoglobulin Market Segmentation
Figure 02. Top Winning Strategies, By Year, 2015-2018*
Figure 03. Top Winning Strategies, By Development, 2015-2018* (%)
Figure 04. Top Winning Strategies, By Company, 2015-2018*
Figure 05. Low Bargaining Power Of Suppliers
Figure 06. High Bargaining Power Of Buyers
Figure 07. High Threat Of Substitution
Figure 08. High Threat Of New Entrants
Figure 09. High Competitive Rivalry
Figure 10. Market Share Analysis, 2017
Figure 11. Global Immunoglobulin Market: Drivers, Restraints, And Opportunities
Figure 01. U.S. Immunoglobulin Market, 2017-2025 ($ Million)
Figure 02. Canada Immunoglobulin Market, 2017-2025 ($ Million)
Figure 03. Mexico Immunoglobulin Market, 2017-2025 ($ Million)
Figure 04. Germany Immunoglobulin Market, 2017-2025 ($ Million)
Figure 05. France Immunoglobulin Market, 2017-2025 ($ Million)
Figure 06. UK Immunoglobulin Market, 2017-2025 ($ Million)
Figure 07. Italy Immunoglobulin Market, 2017-2025 ($ Million)
Figure 08. Spain Immunoglobulin Market, 2017-2025 ($ Million)
Figure 09. Russia Immunoglobulin Market, 2017-2025 ($ Million)
Figure 10. Rest Of Europe Immunoglobulin Market, 2017-2025 ($ Million)
Figure 11. Japan Immunoglobulin Market, 2017-2025 ($ Million)
Figure 12. China Immunoglobulin Market, 2017-2025 ($ Million)
Figure 13. India Immunoglobulin Market, 2017-2025 ($ Million)
Figure 14. Australia Immunoglobulin Market, 2017-2025 ($ Million)
Figure 15. Australia Immunoglobulin Market, 2017-2025 ($ Million)
Figure 16. Taiwan Immunoglobulin Market, 2017-2025 ($ Million)
Figure 17. Rest Of Asia-Pacific Immunoglobulin Market, 2017-2025 ($ Million)
Figure 18. Brazil Immunoglobulin Market, 2017-2025 ($ Million)
Figure 19. South Africa Immunoglobulin Market, 2017-2025 ($ Million)
Figure 20. Saudi Arabia Immunoglobulin Market, 2017-2025 ($Million)
Figure 21. Argentina Immunoglobulin Market, 2017-2025 ($Million)
Figure 22. Rest Of LAMEA Immunoglobulin Market, 2017-2025 ($Million)
Figure 23. Baxter: Net Sales, 2015-2017 ($Million)
Figure 24. Baxter: Revenue Share By Segment, 2017 (%)
Figure 25. Baxter: Revenue Share By Geography, 2017 (%)
Figure 26. BIoTest: Net Sales, 2015-2017 ($Million)
Figure 27. BIoTest: Revenue Share By Segment, 2017 (%)
Figure 28. BIoTest: Revenue Share By Geography, 2017 (%)
Figure 29. Csl: Net Sales, 2015-2017 ($Million)
Figure 30. Csl: Revenue Share By Segment, 2017 (%)
Figure 31. Csl: Revenue Share By Geography, 2017 (%)
Figure 32. Grifols: Net Sales, 2015-2017 ($Million)
Figure 33. Grifols: Revenue Share By Segment, 2017 (%)
Figure 34. Grifols: Revenue Share By Geography, 2017 (%)
Figure 35. Lfb: Net Sales, 20142016 ($Million)
Figure 36. Lfb: Revenue Share By Product Segment, 2016 (%)
Figure 37. Lfb: Revenue Share By Geography, 2016 (%)
Figure 38. Octapharma: Net Sales, 2015-2017 ($Million)
Figure 39. Bayer: Net Sales, 2015-2017 ($Million)
Figure 40. Bayer: Revenue Share By Segment, 2017 (%)
Figure 41. Bayer: Revenue Share By Geography, 2017 (%)
Figure 42. Kedrion: Net Sales, 2015-2017 ($Million)
Figure 43. Kedrion: Revenue Share By Geography, 2017 (%)
Figure 44. Shire: Net Sales, 2015-2017 ($Million)
Figure 45. Shire: Revenue Share By Product, 2017 (%)
Figure 46. Shire: Revenue Share By Geography, 2017 (%)
Figure 47. China Biologic Net Sales, 2015-2017 ($Million)
Note: Product cover images may vary from those shown
3 of 4
According to this report titled, 'Immunoglobulin Market by Application, Product Type, and Mode of Delivery: Global Opportunity Analysis and Industry Forecast, 2018-2025', the immunoglobulin market accounted for $9,851 million in 2017, and is projected to reach $17,501 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulin is a blood/plasma product, which is prepared from the serum of multiple of donors, and is used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. Immunoglobulin is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. Prevalence of various antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness towards antibody deficiency, and rare immune disorders among patient population drive the growth of the immunoglobulin market.
Based on application segment, hypogammaglobulinemia was the largest revenue contributor in 2017 toward market growth and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.
Key Findings of the Immunoglobulin Market:
Myasthenia Gravis segment is projected to grow at the fastest rate during the analysis period.
Hypogammaglobulinemia was the highest revenue contributor in 2017 and is expected to continue its dominance during the forecast period.
North America dominated global immunoglobulins market and is projected to grow at a CAGR of 7.3%.
Saudi Arabia is expected to grow at the fastest rate in the LAMEA region, registering a CAGR of 9.1%.
LAMEA was the fastest growing segment growing at a CAGR of 10.2%.
In 2017, North America accounted for maximum contribution to the total revenue generated, followed by Asia-Pacific. The major factors responsible for the growth of the immunoglobulin market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. and the presence of large plasma production facilities.
The key companies profiled in the report include Baxter international Inc., CSL Ltd, Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products Inc., Shire (Baxalta), and Bayer Healthcare.
Immunoglobulin is a blood/plasma product, which is prepared from the serum of multiple of donors, and is used to treat patients with antibody deficiency. The isolated plasma product is clinically treated and purified to Ig, which further facilitates the treatment. Immunoglobulin is applicable in various fields such as hematology, immunology, neurology, dermatology, nephrology, ophthalmology, and rheumatology. Prevalence of various antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in immunoglobulin indications, improved production & purification processes, growth in awareness towards antibody deficiency, and rare immune disorders among patient population drive the growth of the immunoglobulin market.
Based on application segment, hypogammaglobulinemia was the largest revenue contributor in 2017 toward market growth and is anticipated to continue this trend in the near future. Large patient population, lack of effective substitute treatment, and early adoption of immunoglobulin for the treatment of hypogammaglobulinemia are expected to boost the growth of this segment.
Key Findings of the Immunoglobulin Market:
Myasthenia Gravis segment is projected to grow at the fastest rate during the analysis period.
Hypogammaglobulinemia was the highest revenue contributor in 2017 and is expected to continue its dominance during the forecast period.
North America dominated global immunoglobulins market and is projected to grow at a CAGR of 7.3%.
Saudi Arabia is expected to grow at the fastest rate in the LAMEA region, registering a CAGR of 9.1%.
LAMEA was the fastest growing segment growing at a CAGR of 10.2%.
In 2017, North America accounted for maximum contribution to the total revenue generated, followed by Asia-Pacific. The major factors responsible for the growth of the immunoglobulin market in these regions include high adoption rate in developed and populous countries such as Japan and the U.S. and the presence of large plasma production facilities.
The key companies profiled in the report include Baxter international Inc., CSL Ltd, Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products Inc., Shire (Baxalta), and Bayer Healthcare.
Note: Product cover images may vary from those shown
4 of 4
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
